|
Gene: COMMD3 |
Gene summary for COMMD3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | COMMD3 | Gene ID | 23412 |
Gene name | COMM domain containing 3 | |
Gene Alias | BUP | |
Cytomap | 10p12.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9UBI1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23412 | COMMD3 | SYSMH6 | Human | Oral cavity | OSCC | 6.40e-16 | 4.92e-01 | 0.1275 |
23412 | COMMD3 | P4_S8_cSCC | Human | Skin | cSCC | 1.42e-04 | 7.43e-02 | -0.3095 |
23412 | COMMD3 | P5_S10_cSCC | Human | Skin | cSCC | 1.52e-02 | -3.79e-02 | -0.299 |
23412 | COMMD3 | P1_cSCC | Human | Skin | cSCC | 5.93e-28 | 9.42e-01 | 0.0292 |
23412 | COMMD3 | P2_cSCC | Human | Skin | cSCC | 2.41e-21 | 5.33e-01 | -0.024 |
23412 | COMMD3 | P4_cSCC | Human | Skin | cSCC | 9.46e-18 | 6.01e-01 | -0.00290000000000005 |
23412 | COMMD3 | P10_cSCC | Human | Skin | cSCC | 1.47e-31 | 8.57e-01 | 0.1017 |
23412 | COMMD3 | cSCC_p8 | Human | Skin | cSCC | 3.11e-04 | 2.48e-02 | -0.1971 |
23412 | COMMD3 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 4.82e-02 | -1.52e-01 | 0.02 |
23412 | COMMD3 | male-WTA | Human | Thyroid | PTC | 5.81e-19 | 5.23e-02 | 0.1037 |
23412 | COMMD3 | PTC01 | Human | Thyroid | PTC | 2.34e-13 | 1.23e-01 | 0.1899 |
23412 | COMMD3 | PTC04 | Human | Thyroid | PTC | 3.24e-18 | 7.02e-02 | 0.1927 |
23412 | COMMD3 | PTC05 | Human | Thyroid | PTC | 5.40e-10 | 6.03e-01 | 0.2065 |
23412 | COMMD3 | PTC06 | Human | Thyroid | PTC | 3.76e-22 | 6.20e-01 | 0.2057 |
23412 | COMMD3 | PTC07 | Human | Thyroid | PTC | 5.74e-43 | 5.98e-01 | 0.2044 |
23412 | COMMD3 | ATC09 | Human | Thyroid | ATC | 2.46e-05 | 6.09e-02 | 0.2871 |
23412 | COMMD3 | ATC11 | Human | Thyroid | ATC | 1.42e-07 | 4.19e-01 | 0.3386 |
23412 | COMMD3 | ATC12 | Human | Thyroid | ATC | 1.17e-10 | 1.41e-01 | 0.34 |
23412 | COMMD3 | ATC13 | Human | Thyroid | ATC | 5.78e-29 | 6.63e-01 | 0.34 |
23412 | COMMD3 | ATC1 | Human | Thyroid | ATC | 1.57e-03 | 5.41e-02 | 0.2878 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
COMMD3 | SNV | Missense_Mutation | novel | c.557N>T | p.Ser186Leu | p.S186L | Q9UBI1 | protein_coding | deleterious(0.01) | benign(0.14) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
COMMD3 | SNV | Missense_Mutation | rs143840494 | c.391C>T | p.Arg131Cys | p.R131C | Q9UBI1 | protein_coding | deleterious(0.05) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
COMMD3 | deletion | Frame_Shift_Del | c.298delN | p.Cys101AlafsTer11 | p.C101Afs*11 | Q9UBI1 | protein_coding | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
COMMD3 | SNV | Missense_Mutation | novel | c.479N>T | p.Ser160Phe | p.S160F | Q9UBI1 | protein_coding | deleterious(0.01) | possibly_damaging(0.58) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
COMMD3 | SNV | Missense_Mutation | novel | c.131N>T | p.Ala44Val | p.A44V | Q9UBI1 | protein_coding | tolerated(0.05) | benign(0.305) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
COMMD3 | SNV | Missense_Mutation | rs143840494 | c.391C>T | p.Arg131Cys | p.R131C | Q9UBI1 | protein_coding | deleterious(0.05) | benign(0.007) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
COMMD3 | SNV | Missense_Mutation | c.498N>G | p.Ile166Met | p.I166M | Q9UBI1 | protein_coding | deleterious(0) | benign(0.347) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
COMMD3 | SNV | Missense_Mutation | novel | c.379G>A | p.Asp127Asn | p.D127N | Q9UBI1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
COMMD3 | SNV | Missense_Mutation | novel | c.326N>G | p.Asn109Ser | p.N109S | Q9UBI1 | protein_coding | tolerated(0.78) | benign(0.138) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
COMMD3 | SNV | Missense_Mutation | c.182N>G | p.His61Arg | p.H61R | Q9UBI1 | protein_coding | tolerated(0.12) | benign(0.417) | TCGA-DD-A39V-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |